[go: up one dir, main page]

HN2010002074A - Tiazolopiridin-2-iloxi-fenily tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa - Google Patents

Tiazolopiridin-2-iloxi-fenily tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa

Info

Publication number
HN2010002074A
HN2010002074A HN2010002074A HN2010002074A HN2010002074A HN 2010002074 A HN2010002074 A HN 2010002074A HN 2010002074 A HN2010002074 A HN 2010002074A HN 2010002074 A HN2010002074 A HN 2010002074A HN 2010002074 A HN2010002074 A HN 2010002074A
Authority
HN
Honduras
Prior art keywords
iloxi
tiazolopiridin
fenil
modulators
tiazolopirazin
Prior art date
Application number
HN2010002074A
Other languages
English (en)
Inventor
M Bacani Genesis
Eunice Y Broggini
Christa C Cheung
Xiaohu Deng Chrovian
M Fourie Anne
Gomez Cheryl A Laurent
Aaron M Kearney Grice
M Landry-Bayle Adrienne
Lee-Dutra Alice
T Liang Jimmy
Lochner Susanne
S Mani Neelakandha
Santillan Alejsandro Jr
C Sappey Kathleen
Sepassi Kia
M Tanis Virginia
T Wickboldt Alvah
J M Wiener John
Zinser Hartmut
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HN2010002074A publication Critical patent/HN2010002074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE TIAZOLOPIRIDIN-2-ILOXI-FENIL Y TIAZOLOPIRAZIN-2-ILOXI FENIL AMINA UTILES COMO MODULADORES DE LA LTA4 HIDROLASA(LTA4H). ESOS COMPUESTOS SE PUEDEN USAR EN COMPOSICIONES FARMACEUTICAS Y METODOS PARA LA MODULACION DE LTA4H Y PARA EL TRATAMIENTO DE ESTADOS DE ENFERMEDAD, TRASTORNOS Y AFECCIONES MEDIADOS POR LA ACTIVIDAD DE LA LTA4 HIDROLASA.
HN2010002074A 2008-04-11 2010-10-11 Tiazolopiridin-2-iloxi-fenily tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa HN2010002074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4434908P 2008-04-11 2008-04-11
US14912909P 2009-02-02 2009-02-02

Publications (1)

Publication Number Publication Date
HN2010002074A true HN2010002074A (es) 2012-12-03

Family

ID=41130551

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010002074A HN2010002074A (es) 2008-04-11 2010-10-11 Tiazolopiridin-2-iloxi-fenily tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa

Country Status (35)

Country Link
US (3) US7939527B2 (es)
EP (2) EP2336125B1 (es)
JP (2) JP5530423B2 (es)
KR (1) KR101228378B1 (es)
CN (1) CN102056933B (es)
AR (1) AR072353A1 (es)
AU (1) AU2009234140B2 (es)
BR (1) BRPI0911336A2 (es)
CA (1) CA2721099C (es)
CL (1) CL2009000877A1 (es)
CO (1) CO6260069A2 (es)
CY (1) CY1114628T1 (es)
DK (2) DK2268646T3 (es)
EA (1) EA018802B1 (es)
EC (1) ECSP10010558A (es)
ES (2) ES2440746T3 (es)
HN (1) HN2010002074A (es)
HR (2) HRP20131192T1 (es)
IL (2) IL208480A (es)
JO (1) JO2911B1 (es)
MX (1) MX2010011154A (es)
MY (1) MY157597A (es)
NI (1) NI201000168A (es)
NZ (2) NZ588341A (es)
PE (1) PE20091779A1 (es)
PH (1) PH12013500094B1 (es)
PL (2) PL2336125T3 (es)
PT (2) PT2268646E (es)
RS (2) RS53081B (es)
SI (2) SI2268646T1 (es)
SV (1) SV2010003694A (es)
TW (2) TW201420100A (es)
UY (1) UY31760A (es)
WO (1) WO2009126806A2 (es)
ZA (1) ZA201008054B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
CN102056933B (zh) * 2008-04-11 2014-09-17 詹森药业有限公司 作为白三烯a4水解酶调节剂的噻唑并吡啶-2-基氧基-苯基和噻唑并吡嗪-2-基氧基-苯基胺类
WO2013134226A1 (en) * 2012-03-06 2013-09-12 Boehringer Ingelheim International Gmbh Benzodioxanes for inhibiting leukotriene production
WO2013131901A1 (en) 2012-03-06 2013-09-12 Boehringer Ingelheim International Gmbh Benzodioxanes in combination with other actives for inhibiting leukotriene production
JP6256467B2 (ja) 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するピラゾール誘導体
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
RU2690489C2 (ru) * 2013-03-14 2019-06-04 Селтакссис, Инк. Ингибиторы лейкотриен а4-гидролазы
JP2016513681A (ja) 2013-03-14 2016-05-16 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
AU2019278935B2 (en) 2018-05-31 2025-02-13 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
JP7680955B2 (ja) * 2019-01-11 2025-05-21 ネイジス ファーマシューティカルズ インコーポレイテッド ロイコトリエン合成阻害剤

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008A (en) * 1847-03-13 Machinery for cleaning
IL59004A0 (en) * 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
FR2446823A1 (fr) 1979-01-16 1980-08-14 Delalande Sa Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique
FR2476088A2 (fr) * 1979-01-16 1981-08-21 Delalande Sa Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique
US4329466A (en) * 1979-01-16 1982-05-11 Delalande S.A. Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives
US4321378A (en) * 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
US4424358A (en) * 1979-01-16 1984-01-03 Delalande S.A. β-3-Amino nor-tropane compounds
US4352802A (en) * 1980-06-10 1982-10-05 Beecham Group Limited Bicyclo[3.3.1]nonyl-benzamide
NZ199080A (en) * 1980-12-12 1984-07-31 Beecham Group Ltd 2-alkoxy-4-amino-5-alkylsulphonyl-n-(3beta-(8-hydrocarbyl-8-azabicyclo (3,2,1)octyl))benzamides
US4432983A (en) * 1981-04-30 1984-02-21 Research Corporation Conformationally restricted histamine H2 -receptor antagonists containing a tropane ring
DE3137996A1 (de) * 1981-09-24 1983-04-28 Hoechst Ag, 6230 Frankfurt Heterocyclische phenylaether, verfahren zu deren herstellung und diese enthaltende herbizide mittel
US4571396A (en) * 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
NZ222047A (en) 1986-10-08 1991-01-29 Bristol Myers Co Quinoline - or naphthyridine - carboxylic acid anti-bacterial agents
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
JPS63170356A (ja) 1986-12-30 1988-07-14 Yamanouchi Pharmaceut Co Ltd アニリン誘導体及びその製造法
FI91859C (fi) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
US5070094A (en) 1989-09-05 1991-12-03 G. D. Searle & Co. N-benzyltropaneamides
US5220063A (en) * 1991-05-10 1993-06-15 Hoechst Celanese Corporation Method for the preparation of arylalkanolacylamides
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
TW251287B (es) 1993-04-30 1995-07-11 Nissei Co Ltd
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US5794887A (en) * 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
PT880363E (pt) * 1996-02-13 2002-12-31 Searle & Co Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4
US6110994A (en) * 1996-06-14 2000-08-29 Cabot Corporation Polymeric products containing modified carbon products and methods of making and using the same
US6110944A (en) 1997-03-12 2000-08-29 G. D. Searle & Co. LTA4, hydrolase inhibitors
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6432976B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6559140B2 (en) 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
FR2831884B1 (fr) * 2001-11-02 2003-12-26 Pf Medicament Nouveaux derives amides heteroaromatiques de 3 beta-amino azabicyclooctane, leur procede de preparation et leurs applications en therapeutique
US7152144B2 (en) * 2002-05-29 2006-12-19 Hitachi, Ltd. Centralized storage management method
US7329682B2 (en) * 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
WO2004103959A2 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
DE602004015620D1 (de) * 2003-07-28 2008-09-18 Janssen Pharmaceutica Nv Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
CN101407471A (zh) * 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
JP2008503585A (ja) 2004-06-22 2008-02-07 シェーリング　コーポレイション カンナビノイドレセプターリガンド
GB2415818B (en) 2004-06-30 2008-12-31 Autoliv Dev Arrangement for triggering a vehicle safety device
BRPI0515164A (pt) 2004-09-13 2008-07-08 Ono Pharmaceutical Co derivado heterocìclico nitrogenado e medicamento contendo o mesmo como um ingrediente ativo
BRPI0607742A2 (pt) * 2005-03-31 2009-09-29 Janssen Pharmaceutica Nv moduladores de fenil e piridil lta4h
ES2277745B1 (es) 2005-06-14 2008-06-01 Laboratorios Almirall S.A. Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
JP5363315B2 (ja) 2006-06-06 2013-12-11 コーナーストーン セラピューティクス インコーポレイテッド 新規ピペラジン、医薬組成物、およびその使用方法
WO2008016811A2 (en) 2006-07-31 2008-02-07 Neurogen Corporation Aminopiperidines and realted compounds
EP2121676A1 (en) * 2006-12-19 2009-11-25 Auspex Pharmaceuticals, Inc. Preperation and utility of ccr5 inhibitors
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
TW200932236A (en) * 2007-10-31 2009-08-01 Janssen Pharmaceutica Nv Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase
CN102056933B (zh) * 2008-04-11 2014-09-17 詹森药业有限公司 作为白三烯a4水解酶调节剂的噻唑并吡啶-2-基氧基-苯基和噻唑并吡嗪-2-基氧基-苯基胺类

Also Published As

Publication number Publication date
WO2009126806A3 (en) 2010-03-18
CA2721099C (en) 2017-04-25
RS53081B (en) 2014-06-30
NI201000168A (es) 2015-05-27
TW201002320A (en) 2010-01-16
CA2721099A1 (en) 2009-10-15
RS52712B (en) 2013-08-30
JP2011516571A (ja) 2011-05-26
PL2336125T3 (pl) 2013-06-28
UY31760A (es) 2009-11-10
JP5675943B2 (ja) 2015-02-25
IL208480A0 (en) 2010-12-30
US20090258854A1 (en) 2009-10-15
NZ599853A (en) 2012-08-31
EA018802B1 (ru) 2013-10-30
US20110159563A1 (en) 2011-06-30
CN102056933A (zh) 2011-05-11
CL2009000877A1 (es) 2009-11-27
IL208480A (en) 2014-11-30
AU2009234140B2 (en) 2013-04-11
DK2268646T3 (da) 2013-11-18
PT2268646E (pt) 2013-12-10
JP5530423B2 (ja) 2014-06-25
HRP20131192T1 (hr) 2014-01-17
ES2400875T3 (es) 2013-04-15
EP2336125B1 (en) 2013-01-09
PE20091779A1 (es) 2009-11-14
CY1114628T1 (el) 2016-10-05
PH12013500094A1 (en) 2015-02-23
WO2009126806A2 (en) 2009-10-15
SV2010003694A (es) 2011-03-17
PL2268646T3 (pl) 2014-02-28
SI2336125T1 (sl) 2013-04-30
EP2336125A1 (en) 2011-06-22
MY157597A (en) 2016-06-30
KR101228378B1 (ko) 2013-01-31
AR072353A1 (es) 2010-08-25
HRP20130278T1 (en) 2013-06-30
JO2911B1 (en) 2015-09-15
TW201420100A (zh) 2014-06-01
US20110190503A1 (en) 2011-08-04
IL226244A0 (en) 2013-06-27
PT2336125E (pt) 2013-03-18
ZA201008054B (en) 2012-04-25
US8357684B2 (en) 2013-01-22
SI2268646T1 (sl) 2013-12-31
EP2268646B9 (en) 2014-11-19
EA201071186A1 (ru) 2011-06-30
TWI461196B (zh) 2014-11-21
EP2268646B1 (en) 2013-10-02
JP2014144949A (ja) 2014-08-14
ECSP10010558A (es) 2010-11-30
DK2336125T3 (da) 2013-04-08
WO2009126806A8 (en) 2010-11-18
KR20110013386A (ko) 2011-02-09
IL226244A (en) 2014-12-31
CO6260069A2 (es) 2011-03-22
BRPI0911336A2 (pt) 2021-06-29
HK1152041A1 (en) 2012-02-17
CN102056933B (zh) 2014-09-17
MX2010011154A (es) 2010-12-21
US7939527B2 (en) 2011-05-10
AU2009234140A1 (en) 2009-10-15
PH12013500094B1 (en) 2015-02-23
HK1158208A1 (en) 2012-07-13
EP2268646A2 (en) 2011-01-05
NZ588341A (en) 2012-06-29
ES2440746T3 (es) 2014-01-30

Similar Documents

Publication Publication Date Title
HN2010002074A (es) Tiazolopiridin-2-iloxi-fenily tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
PH12017501306A1 (en) Inhibitors of histone demethylases
CR11292A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112013001613A2 (pt) compostos tricíclicos e métodos para fazer e usar os mesmos.
BR112013027774A2 (pt) novos compostos como moduladores de proteína quinases
BR112012004696A2 (pt) compostos e composições como moduladores da atividade de tlr
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
GEP20146033B (en) N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides usage as wnt signaling modulators
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
MX351028B (es) Determinadadas entidades, composiciones y metodos quimicos.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
UY33276A (es) Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso
BR112014017673A8 (pt) Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
CL2012001072A1 (es) Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
BR112012012261A2 (pt) compostos como moduladores de receptor com utilidade terapêutica